Cyr61 Regulates the Chemosensitivity of Chronic Myeloid Leukemia to Imatinib Mesylate Through the NF ‐κB/Bcl‐2 Pathway

Cancer Science - United States
doi 10.1111/cas.14083
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Cyr61 Decreases Cytarabine Chemosensitivity in Acute Lymphoblastic Leukemia Cells via NF-κB Pathway Activation

International Journal of Molecular Medicine
MedicineGenetics
2018English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research
Cancer ResearchOncology
2004English

Epstein-Barr Virus-Associated Lymphoproliferative Disease During Imatinib Mesylate Treatment for Chronic Myeloid Leukemia

Haematologica
Hematology
2019English

Reduced-Intensity Allogeneic Transplantation Combined With Imatinib Mesylate for Chronic Myeloid Leukemia in First Chronic Phase

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Cyr61 Participates in the Pathogenesis of Acute Lymphoblastic Leukemia by Enhancing Cellular Survival via the AKT/NF-κB Signaling Pathway

Scientific Reports
Multidisciplinary
2016English

COX-2 Regulates E-Cadherin Expression Through the NF-κB/Snail Signaling Pathway in Gastric Cancer

International Journal of Molecular Medicine
MedicineGenetics
2013English

PTEN Regulates BCRP/ABCG2 and the Side Population Through the PI3K/Akt Pathway in Chronic Myeloid Leukemia

PLoS ONE
Multidisciplinary
2014English

Development of Multiple Myeloma in a Patient With Chronic Myeloid Leukemia After Treatment With Imatinib Mesylate

Oncologist
Cancer ResearchMedicineOncology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy